相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Enhancing the Antitumor Activity of Adriamycin and Ionizing Radiation
Wenqing Sun et al.
CANCER RESEARCH (2009)
Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response
Sophie Vibet et al.
FREE RADICAL BIOLOGY AND MEDICINE (2008)
Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor
Hongyu Xue et al.
CLINICAL CANCER RESEARCH (2007)
The effect of seal oil on paclitaxel induced cytotoxicity and apoptosis in breast carcinoma MCF-7 and MDA-MB-231 cell lines
Zheyu Wang et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2007)
Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline:: A role for tumor vascularization
Severine Colas et al.
CLINICAL CANCER RESEARCH (2006)
Effect of docosahexaenoic acid on tissue targeting and metabolism of plasma lipoproteins
Alla Polozova et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2006)
Metabolism of α-linolenic acid in humans
G. C. Burdge
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2006)
Differential sensitization of cancer cells to doxorubicin by DHA:: A role for lipoperoxidation
K Mahéo et al.
FREE RADICAL BIOLOGY AND MEDICINE (2005)
Preoperative oral supplementation with long-chain Ω-3 fatty acids beneficially alters phospholipid fatty acid patterns in liver, gut mucosa, and tumor tissue
Metin Senkal et al.
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION (2005)
Exogenous supplementation with ω-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells
JA Menendez et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2005)
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: A central European cooperative oncology group international, multicenter, prospective, randomized phase III trial
C Zielinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
alpha-tocopherol suppresses mammary tumor sensitivity to anthracyclines in fish oil-fed rats
S Colas et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2005)
Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid
S Colas et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
G Atalay et al.
EUROPEAN JOURNAL OF CANCER (2003)
n-3 polyunsaturated fatty acids decrease mucosal/epidermal reactions and enhance antitumour effect of ionising radiation with inhibition of tumour angiogenesis
B Wen et al.
BRITISH JOURNAL OF CANCER (2003)
Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma
AM Capotorto et al.
JOURNAL OF CHEMOTHERAPY (2003)
Anthracycline-induced cardiac toxicity is not increased by dietary omega-3 fatty acids
E Germain et al.
PHARMACOLOGICAL RESEARCH (2003)
A review of the safety of DHA45-oil
R Kroes et al.
FOOD AND CHEMICAL TOXICOLOGY (2003)
Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice
T Kato et al.
CANCER LETTERS (2002)
Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain
M Lagarde et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2001)
Adriamycin-induced heart failure: mechanisms and modulation
P Singal et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2000)
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results
P Pacini et al.
EUROPEAN JOURNAL OF CANCER (2000)
分享论文
